Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 13 Lymphoma, Follicular 7 Lymphoma, B-Cell, Marginal Zone 5 Waldenstrom Macroglobulinemia 4 Lymphoma, Non-Hodgkin 4 Lymphoma, Mantle-Cell 3 Lymphoma, B-Cell 2 Leukemia, Myeloid, Acute 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Multiple Myeloma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, B-Cell 1 Leukemia 1 Hodgkin Disease 1

Interventions

Rituximab 187 Cyclophosphamide 174 Etoposide 94 Peripheral Blood Stem Cell Transplantation 90 Vincristine 89 Prednisone 80 Doxorubicin 79 Filgrastim 75 fludarabine phosphate 60 Radiotherapy 56 Mycophenolic Acid 41 Melphalan 41 Cytarabine 41 Busulfan 40 Cyclosporine 39 Methotrexate 37 Whole-Body Irradiation 36 Tacrolimus 35 Carmustine 34 Ifosfamide 28 Lenalidomide 27 Granulocyte Colony-Stimulating Factor 27 Antilymphocyte Serum 27 Gemcitabine 25 Carboplatin 25 Methylprednisolone 24 ibritumomab tiuxetan 23 Bortezomib 22 Dexamethasone 21 ibrutinib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, Large B-Cell, Diffuse × idelalisib × Clear all

NCT03576443 2021-10-13

ILIAD

Nordic Lymphoma Group

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡